EPISODE · Dec 4, 2025 · 27 MIN
Advancing Single-Cell Medicine: How One Biosciences Is Shaping Therapeutics with Hedi Ben Brahim
from GSD Venture Studios Podcasts by Gary Fowler · host GSD Venture Studios
Join Hedi Ben Brahim, CEO of One Biosciences and a leading figure in the French biotechnology ecosystem, in an in-depth conversation with Gary Fowler as they explore how single-cell technologies are transforming precision medicine. Learn how One Biosciences is unlocking new therapeutic targets, expanding to the U.S., and navigating the challenges of scaling an innovation-driven biotech company.Insights You’ll Learn:✓ What single-cell analysis enables that traditional drug discovery cannot✓ How One Biosciences identifies new targets for difficult-to-treat diseases✓ Challenges and opportunities in expanding a European biotech to the U.S. market✓ Why computational biology is central to the next wave of precision therapeutics✓ How to build an integrated discovery engine combining wet lab and in-silico innovation✓ Lessons from leading biotech, oncology, and immunotherapy organizations✓ The current biotech landscape — and what founders must prepare for nextWhy This Matters:Single-cell technology is redefining how we understand disease at a molecular level. One Biosciences sits at the forefront of this revolution, combining computational power with multidisciplinary research to accelerate new therapies for complex conditions.Hedi’s leadership—across public policy, oncology, immunotherapy, and biotech scaling—offers rare insight into what it takes to bring breakthrough science from Europe to the global stage.Expert Background:• Chief Executive Officer of One Biosciences• Former CEO of Transgene, a leader in immunotherapy and oncology• Veteran of France’s Ministry of Economy and Ministry of Health• Held leadership roles across biotech, healthtech, and research institutes• Board member at GeNeuro and Kolibri• Recognized expert in precision medicine, oncology, and biotech innovationAbout One Biosciences:One Biosciences leverages advanced single-cell analysis to power a new wave of precision medicine. Its integrated discovery engine fuses computational biology and multidisciplinary expertise to find therapeutic targets for complex, difficult-to-treat diseases. Supported by Institut Curie and Home Biosciences, it is accelerating breakthroughs in drug discovery.💡Perfect For:Biotech founders, researchers, pharma leaders, computational biologists, investors, and anyone interested in the future of precision medicine and next-generation drug discovery.Timely Topic:As precision medicine enters a pivotal decade, single-cell innovation will define the companies that lead the future of therapeutics — and One Biosciences is one of them.Subscribe for more global founder conversations from GSD Venture Studios:https://gsdvs.com#Biotech #PrecisionMedicine #SingleCellAnalysis #DrugDiscovery #Oncology #Immunotherapy #HealthTech #BiotechInnovation #OneBiosciences #HediBenBrahim #GaryFowler #GSDVentureStudios
What this episode covers
Join Hedi Ben Brahim, CEO of One Biosciences and a leading figure in the French biotechnology ecosystem, in an in-depth conversation with Gary Fowler as they explore how single-cell technologies are transforming precision medicine. Learn how One Biosciences is unlocking new therapeutic targets, expanding to the U.S., and navigating the challenges of scaling an innovation-driven biotech company.Insights You’ll Learn:✓ What single-cell analysis enables that traditional drug discovery cannot✓ How One Biosciences identifies new targets for difficult-to-treat diseases✓ Challenges and opportunities in expanding a European biotech to the U.S. market✓ Why computational biology is central to the next wave of precision therapeutics✓ How to build an integrated discovery engine combining wet lab and in-silico innovation✓ Lessons from leading biotech, oncology, and immunotherapy organizations✓ The current biotech landscape — and what founders must prepare for nextWhy This Matters:Single-cell technology is redefining how we understand disease at a molecular level. One Biosciences sits at the forefront of this revolution, combining computational power with multidisciplinary research to accelerate new therapies for complex conditions.Hedi’s leadership—across public policy, oncology, immunotherapy, and biotech scaling—offers rare insight into what it takes to bring breakthrough science from Europe to the global stage.Expert Background:• Chief Executive Officer of One Biosciences• Former CEO of Transgene, a leader in immunotherapy and oncology• Veteran of France’s Ministry of Economy and Ministry of Health• Held leadership roles across biotech, healthtech, and research institutes• Board member at GeNeuro and Kolibri• Recognized expert in precision medicine, oncology, and biotech innovationAbout One Biosciences:One Biosciences leverages advanced single-cell analysis to power a new wave of precision medicine. Its integrated discovery engine fuses computational biology and multidisciplinary expertise to find therapeutic targets for complex, difficult-to-treat diseases. Supported by Institut Curie and Home Biosciences, it is accelerating breakthroughs in drug discovery.💡Perfect For:Biotech founders, researchers, pharma leaders, computational biologists, investors, and anyone interested in the future of precision medicine and next-generation drug discovery.Timely Topic:As precision medicine enters a pivotal decade, single-cell innovation will define the companies that lead the future of therapeutics — and One Biosciences is one of them.Subscribe for more global founder conversations from GSD Venture Studios:https://gsdvs.com#Biotech #PrecisionMedicine #SingleCellAnalysis #DrugDiscovery #Oncology #Immunotherapy #HealthTech #BiotechInnovation #OneBiosciences #HediBenBrahim #GaryFowler #GSDVentureStudios
NOW PLAYING
Advancing Single-Cell Medicine: How One Biosciences Is Shaping Therapeutics with Hedi Ben Brahim
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.